MADISON SQUARE GARDEN SPORTS CORP.

(MSGS)
  Report
Delayed Nyse  -  04:00 2022-07-06 pm EDT
152.87 USD   -1.89%
07/05Macquarie Adjusts Price Target on Madison Square Garden Sports to $230 From $240, Keeps Outperform Rating
MT
06/02Wolfe Research Adjusts Madison Square Garden Sports' Price Target to $231 from $238, Keeps Outperform Rating
MT
05/24Omorpho Inc. announced that it has received $6 million in funding from KB Partners, LLC, Madison Square Garden Sports Corp.
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
150.82(c) 151(c) 153.86(c) 155.82(c) 152.87(c) Last
94 623 56 666 105 230 113 450 94 972 Volume
-0.17% +0.12% +1.89% +1.27% -1.89% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 750 M - -
Net income 2022 14,6 M - -
Net Debt 2022 244 M - -
P/E ratio 2022 331x
Yield 2022 -
Sales 2023 789 M - -
Net income 2023 33,2 M - -
Net Debt 2023 191 M - -
P/E ratio 2023 116x
Yield 2023 -
Capitalization 3 703 M 3 703 M -
EV / Sales 2022 5,26x
EV / Sales 2023 4,94x
Nbr of Employees -
Free-Float 62,4%
More Financials
Company
Madison Square Garden Sports Corp. is a professional sports company that owns and operates a portfolio of assets and featuring recognized teams in all of the sports, including the New York Knickerbockers (Knicks) of the National Basketball Association (NBA) and the New York Rangers (Rangers) of the National Hockey League (NHL). The Company’s other professional franchises include two development league teams,... 
More about the company
Ratings of Madison Square Garden Sports Corp.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about MADISON SQUARE GARDEN SPORTS CORP.
07/05Macquarie Adjusts Price Target on Madison Square Garden Sports to $230 From $240, Keeps..
MT
06/02Wolfe Research Adjusts Madison Square Garden Sports' Price Target to $231 from $238, Ke..
MT
05/24Omorpho Inc. announced that it has received $6 million in funding from KB Partners, LLC..
CI
05/05MADISON SQUARE GARDEN SPORTS CORP. Management's Discussion and Analysis of Financial C..
AQ
05/05TRANSCRIPT : Madison Square Garden Sports Corp., Q3 2022 Earnings Call, May 05, 2022
CI
05/05Earnings Flash (MSGS) MADISON SQUARE GARDEN SPORTS Posts Q3 Revenue $337.8M, vs. Street..
MT
05/05Madison Square Garden Sports Corp. Reports Fiscal 2022 Third Quarter Results
BU
05/05Madison Square Garden Sports Corp. Reports Earnings Results for the Third Quarter and N..
CI
05/03Madison Square Garden Sports Corp. to Host Fiscal 2022 Third Quarter Conference Call
BU
04/01MADISON SQUARE GARDEN SPORTS : Rangers agree to terms with bobby trivigno
PU
03/30New York Knicks & Maker's Mark Partner with Nonprofit Organization ROAR to Help Support..
BU
03/29Evolve IP Named an Official Partner of the New York Rangers
BU
03/29Evolve IP Names an Official Partner of the New York Rangers
CI
03/28MADISON SQUARE GARDEN SPORTS : Rangers acquire maxim letunov
PU
03/21MADISON SQUARE GARDEN SPORTS : Rangers acquire tyler motte
PU
More news
News in other languages on MADISON SQUARE GARDEN SPORTS CORP.
05/05Earnings Flash (MSGS) MADISON SQUARE GARDEN SPORTS affiche un chiffre d'affaires de 337..
05/05Madison Square Garden Sports Corp. annonce ses résultats financiers pour le troisième t..
03/29Evolve IP devient un partenaire officiel des New York Rangers
03/18MISE À JOUR SECTORIELLE : Les valeurs de consommation discrétionnaire ajoutent à la hausse..
03/18MISE À JOUR SECTORIELLE : Consommation
More news
Analyst Recommendations on MADISON SQUARE GARDEN SPORTS CORP.
More recommendations
Chart MADISON SQUARE GARDEN SPORTS CORP.
Duration : Period :
Madison Square Garden Sports Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MADISON SQUARE GARDEN SPORTS CORP.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 152,87 $
Average target price 222,50 $
Spread / Average Target 45,5%
EPS Revisions
Managers and Directors
Andrew Sam Lustgarten President & Chief Executive Officer
Victoria M. Mink CFO, Treasurer & Executive Vice President
James Lawrence Dolan Executive Chairman
Lisa R. Callahan Chief Medical Officer
Richard D. Parsons Independent Director
Sector and Competitors